BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Functional Genetics, Inc. And ProBioGen AG Close Antibody Production Agreement


11/12/2008 3:28:09 PM

Berlin, November 12, 2008 – Functional Genetics, a biotech company using innovative science to develop broad spectrum anti-viral therapeutics for infectious diseases, and ProBioGen AG, a leading cell specialist for production of biopharmaceuticals, today announced the successful completion of a cell line development contract and the start of an antibody production agreement.

Functional Genetics’ pipeline includes broad spectrum anti-viral small molecules and antibodies in various stages of preclinical development. The monoclonal antibody being produced by ProBioGen targets TSG101 and has the potential for broad spectrum antiviral applications against hemorrhagic fever viruses including Ebola and Marburg as well as HIV, Influenza, RSV and PIV. Toward this objective, ProBioGen has already successfully developed a new production cell line for the TSG101 program which matched yield expectations. Under the contract, ProBioGen will now start process development and will produce pre-clinical material and – later on - GMP-material for clinical trials, which are anticipated to start in early 2010. Functional Genetics work is sponsored by the Defense Threat Reduction Agency (DTRA) at Fort Belvoir for the treatment of hemorrhagic fever viruses.

„We are impressed with ProBioGen´s track record in the field of antibody production and their deep scientific insights, which led to a tailored and accelerated development project,” commented Michael Kinch, VP R&D at Functional Genetics. „We are confident that our antibody will enter clinical trials faster than we anticipated looking at conventional development programs.”

„This production agreement with Functional Genetics strengthens our customer base and business activities in the U.S. and proves our leadership in the development of cell lines and the production of antibodies at medium scale capacities,” added Dr Gabriele Schneider, VP Business Development at ProBioGen.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES